Introduction
Dear Candidate,
Thank you for expressing an interest in the Non-Executive Director roles on the NICE Board.
Since NICE was established in 1999, we’ve delivered vast amounts of guidance. More than many other health technology assessment bodies across the globe. But health and care has changed rapidly since we were created. Digital health technologies, with the potential to transform healthcare, are constantly emerging. Evidence-based healthcare is evolving. The amount of health and care data has grown exponentially, and the healthcare system is facing unprecedented workforce and capacity pressures.
The life sciences sector is a jewel in our country’s crown that stretches from world leading research in our universities and institutes to a flourishing industrial sector encompassing drugs, devices, diagnostics, med-tech, data and more. To help practitioners and commissioners get the best care to patients fast, while ensuring value for the taxpayer, we must work with our partners in the health and social care system to support this sector as we actively contribute to the Government’s health and economic growth missions, so that advances for patients in the future can be assured.
We're therefore taking measures to adapt and our Board has a central role in successfully implementing our vision for change.
We are continuing to ensure we maintain our independence, transparency and rigour, but are focusing on improving the relevance, timeliness, usability, and demonstrable impact of our guidance as we evolve our priorities and approach to meet the changing needs of our users and the emerging 10 year NHS Plan.
We will deliver these aims by:
• Providing high quality, timely advice, including in key areas of new innovation. We are seeking to improve the time taken to develop and update our guidance by aligning and digitising our guidance producing processes and introducing continuous improvement methods. We are exploring opportunities to improve our assessment of value in areas such as health inequalities and piloting ways to assess value in the late stage of the innovation lifecycle.
• Ensuring our advice is relevant to people and communities and the health and care system, by prioritising topics for NICE guidance through criteria on which we have consulted with the public and agreed with system partners, and sustain the growth in our HealthTech programme, aiming to link it into a seamless pathway from regulation to funding.
• Improving the useability of our advice by incorporating relevant Technology Appraisals about new medicines and HealthTech in our guidelines and making the right advice easier to find.
• Increasing the impact of our advice by working with partners to increase the uptake of NICE's recommendations and expanding the ways in which people and communities can contribute to our guidance.
The Board will help the organisation to navigate these challenges. To do this, we need individuals with a range of specific technical skills but equally important are an intellectual curiosity, a deep commitment to improving health and care in England and a desire to contribute to collective deliberations that will ensure that NICE is fit for the challenges ahead.
Thank you for taking the time to apply and I look forward to meeting you in due course.
Sharmila Nebhrajani OBE
Chair of NICE
Appointment description
Ministers are seeking to make 3 appointments to the board of National Institute for Health and Care Excellence (NICE).
As a Non-Executive Member, you will:
• contribute to the development of the Institute’s objectives, ensuring that they are appropriately reflected in its plans, and assist in monitoring progress towards meeting these objectives
• contribute to the governance of the Institute by ensuring that the Institute’s senior management team is held to account for the performance of the organisation, and help ensure that the Institute meets the highest possible standards in its conduct
• provide counsel, advice and support to the executive team, playing the role of ‘critical friend’ where necessary. Draw to the attention of the Chair or the Chief Executive any matters that may adversely affect the Institute’s reputation
• with other members of the Board, ensure the establishment and maintenance of good working relationships with NICE’s key stakeholders and, when required, act as an ambassador for the Institute to its stakeholders
• sit alongside 4 independent panel members to hear 1-2 appeals against NICE’s technology appraisal and highly specialised technologies guidance each year
• when required, act as a member of one or more of the Board’s sub-committees (Audit, Remuneration) and, as required, take part in the appointment of the Chief Executive and other Directors.
Organisation description
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body that works to improve the quality, sustainability and productivity of health and social care. NICE helps practitioners and commissioners get the best care to people fast, while ensuring value for the taxpayer.
To deliver its purpose, NICE produces high quality guidance that is timely, relevant, useable and impactful. Since its establishment in 1999, NICE has developed a reputation as a leader in evidence-based health and social care policy, assessment and decision making for the nation and across the world.
NICE assesses the cost effectiveness of most new medicines through its technology appraisal programme and operates a separate highly specialised technologies programme for the evaluation of a small number of very high-cost drugs for rare diseases. The NHS is legally required to fund drugs recommended by NICE.
In 2023/24, NICE published or updated 188 pieces of high-quality guidance across all of its programmes It also has a significant portfolio of over 300 guidelines across clinical, public health, and social care.
NICE has a key role in supporting Government priorities for the health and care system and is a key partner in the development of the Government’s 10-year plan to radically reform the NHS. It works with the Government and organisations such as NHS England, MHRA and NIHR to support patient access to effective new treatments and ensure the UK remains an attractive place for the life sciences industry.
NICE’s remit across health care, public health and social care means it is well placed to provide a system-wide perspective at the national, regional and local levels, including supporting the Integrated Care Systems. Its work is high-profile and is of significant public, media and Parliamentary interest. Further information on NICE and its portfolio of work can be found here: https://www.nice.org.uk/
NICE’s offices are currently located in Stratford (London) and Manchester, and NICE’s total funding for 2023/24 was £88m. The current whole-time equivalent workforce is 815.
Useful links:
Board composition
Main office:
2nd Floor, 2 Redman Place
London
E20 1JQ
NICE hold 6 board meetings a year. They are open to the public and held in different locations across the country. Upcoming meetings are scheduled for:
Wednesday 19 March 2025
Regulation of appointment
This post is regulated by the Commissioner for Public Appointments. For more information, please refer to the
Commissioner’s website